Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Announces Opening of two New Ablatherm-HIFU Excellence Urology Centers in the U.S.
    University of Chicago Medicine - Dr. A. Shalhav, Chair of Urology Surgery and Director of Robotic Surgery  Vituro Health LLC - Dr. S. Scionti , Medical Director and Director of The Scionti Prostate Center in Sarasota, FL LYON, France , September 19, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global
View HTML
Toggle Summary EDAP Announces New Board Member
U.S. Industry Veteran Rob Michiels Elected Director
View HTML
Toggle Summary EDAP Announces New Ablatherm HIFU Site at Cleveland Clinic Canada in Toronto, Canada
Ablatherm HIFU Operated by Exclusive Distributor in Canada, Maple Leaf HIFU
View HTML
Toggle Summary EDAP Announces Multiple Oral Presentations at the 21st International Symposium on Therapeutic Ultrasound
LYON, France, June 6, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that three oral presentations will be delivered on its HIFU developments at the 21 st Annual International Symposium on Therapeutic Ultrasound (ISTU), which
View HTML
Toggle Summary EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
  Meeting to Showcase EDAP’s Focal One ® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the Company
View HTML
Toggle Summary EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Web cast scheduled for Tuesday, April 18 th at 12:00 p.m. PDT (3:00 p.m. EDT) LYON, France, April 10, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today
View HTML
Toggle Summary EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer LYON, France , Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is
View HTML
Toggle Summary EDAP Announces Initial Ablatherm-HIFU Treatments at Premiere M.D. Anderson Cancer Center in Ongoing Phase II/III Clinical Trial
EDAP Announces Initial Ablatherm-HIFU Treatments at Premiere M.D. Anderson Cancer Center in Ongoing Phase II/III Clinical Trial LYON, France, July 17, 2008 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that urologists at the University of Texas M.D.
View HTML
Toggle Summary EDAP Announces Hiring of MedTech Industry Veteran Ryan Rhodes as CEO of Company’s U.S. Subsidiary
Appointment brings highly experienced medical technology and commercialization leader to drive EDAP’s US expansion focus. Career accomplishments include 14 years at Intuitive Surgical, where he played a leading role in global clinical expansion of robotic surgery in multiple specialties including
View HTML
Toggle Summary EDAP Announces Focal One® HIFU Sale to Foch Hospital, Paris
Growing Adoption of Focal One HIFU in France
View HTML